Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
  1. Home
  2. Products
  3. 502940260

Cayman Chemical ML-221, Purity: ≥98%, CAS: 877636-42-5, 25 mg
SDP

Catalog No. 502940260
Encompass_Preferred

An APJ receptor antagonist (IC50 = 4.8 μM); selective for APJ over AT1 (IC50 = >78 μM); antagonizes apelin 13-induced activation of APJ in cAMP and β-arrestin recruitment assays (IC50s = 0.7 and 1.75 μM, respectively); inhibits proliferation and angiogenesis in Mz-ChA-1 cholangiocarcinoma cells from 5-15 μM; reduces tumor growth in a Mz-ChA-1 mouse xenograft model at 150 μg/kg; reduces sciatic CCI-induced mechanical allodynia and heat hyperalgesia in rats at 10 μg/animal; inhibits pathological angiogenesis and enhances normal vessel recovery in retinal ischemic regions in a mouse model of oxygen-induced retinopathy

Catalog No. 50-294-0260 Supplier Cayman Chemical Supplier No. 2731325 MG
May include imposed supplier surcharges.
Add to Cart
Add to Cart

missing translation for 'validMainframeMsg'

An APJ receptor antagonist (IC50 = 4.8 μM); selective for APJ over AT1 (IC50 = >78 μM); antagonizes apelin 13-induced activation of APJ in cAMP and β-arrestin recruitment assays (IC50s = 0.7 and 1.75 μM, respectively); inhibits proliferation and angiogenesis in Mz-ChA-1 cholangiocarcinoma cells from 5-15 μM; reduces tumor growth in a Mz-ChA-1 mouse xenograft model at 150 μg/kg; reduces sciatic CCI-induced mechanical allodynia and heat hyperalgesia in rats at 10 μg/animal; inhibits pathological angiogenesis and enhances normal vessel recovery in retinal ischemic regions in a mouse model of oxygen-induced retinopathy

Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.